Publication

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation

Abstract
Background: Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumour location; treatments delivered; time since treatment; current medication;) were explored with regression analyses. Results: In total, 237 patients M=9.9 years post-diagnosis (sd=4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (post-hoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning.
Author
Boele, Florien W
Frances, Sé M
Darlix, Amélie
Ducray, Francois
Cartalat, Stéphanie
Guerdoux, Estelle
Tabouret, Emeline
Burger, Michael C
Rydén, Isabelle
Malmstrom, Annika
Vauleon, Elodie
Kazda, Tomas
Renovanz, Mirjam
Werner, Jan-Michael
Welsh, Liam
Sanghera, Paul
Dehais, Caroline
Desideri, Isacco
McBain, Catherine
Mehta, Shaveta
Lord, Hannah
Jena, Rajesh
Foweraker, Karen
Ashkan, Keyoumars
Engelhardt, Julien
Bourg, Veronique
Herrlinger, Ulrich
McLean, Aaron Lawson
Hertler, Caroline
Haldbo-Classen, Lene
Dahlrot, Rikke H
Noel, Georges
Durando, Xavier
Hrab, Ioana
Razis, Evangelia
Weller, Michael
Muhic, Aida
Klein, Martin
Citations
Google Scholar:
Lookup
Altmetric:
Date
2025-07-19
Type
Article
Subject
Oncology. Pathology., Neurology
Collections
UHB Oncology
Show all metadata
Citation
Boele FW, Frances SM, Darlix A, Ducray F, Cartalat S, Guerdoux E, Tabouret E, Burger MC, Rydén I, Malmstrom A, Vauleon E, Kazda T, Renovanz M, Werner JM, Welsh L, Sanghera P, Dehais C, Desideri I, McBain C, Mehta S, Lord H, Jena R, Foweraker K, Ashkan K, Engelhardt J, Bourg V, Herrlinger U, McLean AL, Hertler C, Haldbo-Classen L, Dahlrot RH, Noel G, Durando X, Hrab I, Razis E, Weller M, Muhic A, Klein M. Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation. Neuro Oncol. 2025 Jul 19:noaf172. doi: 10.1093/neuonc/noaf172. Epub ahead of print.
Journal / Source Title
Neuro-Oncology
DOI
10.1093/neuonc/noaf172
URI
https://mider.dspace7.openrepository.com/handle/20.500.14200/8144
PMID
40692477
Publisher
Oxford University Press
Publisher’s URL
https://academic.oup.com/neuro-oncology
Publisher’s statement
Note / Copyright